235 related articles for article (PubMed ID: 12530522)
1. Cellular and molecular aspects of drugs of the future: oxaliplatin.
Di Francesco AM; Ruggiero A; Riccardi R
Cell Mol Life Sci; 2002 Nov; 59(11):1914-27. PubMed ID: 12530522
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond E; Faivre S; Woynarowski JM; Chaney SG
Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
[TBL] [Abstract][Full Text] [Related]
3. Specificity of platinum-DNA adduct repair.
Chaney SG; Vaisman A
J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
[TBL] [Abstract][Full Text] [Related]
4. East-west fusion-necrosis and apoptosis acting in concert by demethylcantharidin-integrated platinum complexes.
Pang SK; So WK; Ho YP; Au-Yeung CF
Anticancer Agents Med Chem; 2014 Jun; 14(5):756-61. PubMed ID: 24476313
[TBL] [Abstract][Full Text] [Related]
5. Spontaneous translocation of antitumor oxaliplatin, its enantiomeric analogue, and Cisplatin from one strand to another in double-helical DNA.
Malina J; Natile G; Brabec V
Chemistry; 2013 Sep; 19(36):11984-91. PubMed ID: 23873652
[TBL] [Abstract][Full Text] [Related]
6. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
7. Transcription inhibition by platinum-DNA cross-links in live mammalian cells.
Ang WH; Myint M; Lippard SJ
J Am Chem Soc; 2010 Jun; 132(21):7429-35. PubMed ID: 20443565
[TBL] [Abstract][Full Text] [Related]
8. cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects.
Lovejoy KS; Todd RC; Zhang S; McCormick MS; D'Aquino JA; Reardon JT; Sancar A; Giacomini KM; Lippard SJ
Proc Natl Acad Sci U S A; 2008 Jul; 105(26):8902-7. PubMed ID: 18579768
[TBL] [Abstract][Full Text] [Related]
9. Protein interactions with platinum-DNA adducts: from structure to function.
Chaney SG; Campbell SL; Temple B; Bassett E; Wu Y; Faldu M
J Inorg Biochem; 2004 Oct; 98(10):1551-9. PubMed ID: 15458816
[TBL] [Abstract][Full Text] [Related]
10. Ongoing and unsaid on oxaliplatin: the hope.
Cvitkovic E
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):8-11. PubMed ID: 9647613
[TBL] [Abstract][Full Text] [Related]
11. Revisiting [PtClâ‚‚(cis-1,4-DACH)]: an underestimated antitumor drug with potential application to the treatment of oxaliplatin-refractory colorectal cancer.
Margiotta N; Marzano C; Gandin V; Osella D; Ravera M; Gabano E; Platts JA; Petruzzella E; Hoeschele JD; Natile G
J Med Chem; 2012 Aug; 55(16):7182-92. PubMed ID: 22788918
[TBL] [Abstract][Full Text] [Related]
12. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
[TBL] [Abstract][Full Text] [Related]
13. Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells.
Gibbons GR; Kaufmann WK; Chaney SG
Carcinogenesis; 1991 Dec; 12(12):2253-7. PubMed ID: 1747924
[TBL] [Abstract][Full Text] [Related]
14. Cellular and molecular pharmacology of oxaliplatin.
Raymond E; Faivre S; Chaney S; Woynarowski J; Cvitkovic E
Mol Cancer Ther; 2002 Jan; 1(3):227-35. PubMed ID: 12467217
[TBL] [Abstract][Full Text] [Related]
15. MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA.
Zdraveski ZZ; Mello JA; Farinelli CK; Essigmann JM; Marinus MG
J Biol Chem; 2002 Jan; 277(2):1255-60. PubMed ID: 11705991
[TBL] [Abstract][Full Text] [Related]
16. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
17. Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand.
Kasparkova J; Vojtiskova M; Natile G; Brabec V
Chemistry; 2008; 14(4):1330-41. PubMed ID: 18022972
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.
Rixe O; Ortuzar W; Alvarez M; Parker R; Reed E; Paull K; Fojo T
Biochem Pharmacol; 1996 Dec; 52(12):1855-65. PubMed ID: 8951344
[TBL] [Abstract][Full Text] [Related]
19. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity, cellular uptake, glutathione and DNA interactions of an antitumor large-ring Pt II chelate complex incorporating the cis-1,4-diaminocyclohexane carrier ligand.
Kasparkova J; Suchankova T; Halamikova A; Zerzankova L; Vrana O; Margiotta N; Natile G; Brabec V
Biochem Pharmacol; 2010 Feb; 79(4):552-64. PubMed ID: 19782655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
